Reconstitute using bacteriostatic water, not sterile water
Semax and Selank are Russian-developed nootropic peptides, derivatives of ACTH and tuftsin, with decades of clinical use in Russia and small human trial packages well short of a U.S
As a cofactor for enzymatic reactions, it participates in DNA synthesis and repair, part of cellular maintenance
Angiogenic Pathway Activation Multi-Component Blood Vessel Formation Multiple components contribute to comprehensive angiogenesis through distinct but complementary mechanisms[5]: BPC-157 upregulates VEGFR2 expression and enhances endothelial cell proliferation TB-500 promotes endothelial cell migration and tube formation GHK-Cu stimulates angiogenic growth factor expression and vessel maturation Combined effects result in robust tissue vascularization and nutrient delivery Improved collateral circulation development in ischemic conditions Nitric Oxide System Modulation Vascular Protection BPC-157 influences nitric oxide signaling pathways to support vascular function[6]: Enhanced eNOS phosphorylation leading to controlled NO production Modulation of blood flow and vascular tone Protection against both NO excess and NO deficiency states Coordination with angiogenic effects for comprehensive vascular support Synergistic Advantage: KLOW Blends four-pathway approach enables simultaneous activation of cellular migration (BPC-157/TB-500), matrix synthesis and gene expression modulation (GHK-Cu), robust inflammation control (KPV), and comprehensive angiogenesis
Both remain in phase 3 clinical development programs [16]: Cagrilintide Status: Phase 3 trials ongoing for CagriSema (cagrilintide + semaglutide combination) Expected approval timeline: 2027-2028 for the combination product Monotherapy development pathway unclear Retatrutide Status: Phase 3 trials initiated in 2024-2025 Monotherapy development for obesity and metabolic dysfunction Expected approval timeline: 2028-2029 if trials succeed This regulatory status means any use of these compounds, whether individually or in cagrilintide dosage with retatrutide combinations, occurs in research contexts or through off-label prescribing once (if) individual approvals are obtained
